Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2004-07-21
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients
who have metastatic or recurrent prostate cancer that has not responded to previous hormone
therapy.
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
Completed
NCIC Clinical Trials Group
Phase 2
2004-07-21
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients
who have metastatic or recurrent prostate cancer that has not responded to previous hormone
therapy.
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
Completed
National Cancer Institute (NCI)
Phase 1
2004-12-01
This phase I trial is studying the side effects and best dose of sorafenib in treating
patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of
tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for
their growth.
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Completed
Gynecologic Oncology Group
Phase 2
2004-10-01
Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by
blocking the enzymes necessary for their growth. This phase II trial is studying how well
sorafenib works in treating patients with persistent or recurrent ovarian epithelial or
peritoneal cancer.
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2004-10-01
Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by
blocking the enzymes necessary for their growth. This phase II trial is studying how well
sorafenib works in treating patients with persistent or recurrent ovarian epithelial or
peritoneal cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
